Histone deacetylases (HDACs) represent novel molecular targets for the treatment of various types of cancers, including multiple myeloma (MM). Many HDAC inhibitors have already shown remarkable antitumor activities in the preclinical setting; however, their clinical utility is limited because of unfavorable toxicities associated with their broad range HDAC inhibitory effects. Isoformselective HDAC inhibition may allow for MM cytotoxicity without attendant side effects. In this study, we demonstrated that HDAC3 knockdown and a small-molecule HDAC3 inhibitor BG45 trigger significant MM cell growth inhibition via apoptosis, evidenced by caspase and poly (ADP-ribose) polymerase cleavage. Importantly, HDAC3 inhibition downregulates phosphorylation (tyrosine 705 and serine 727) of signal transducers and activators of transcription 3 (STAT3). Neither interleukin-6 nor bone marrow stromal cells overcome this inhibitory effect of HDAC3 inhibition on phospho-STAT3 and MM cell growth. Moreover, HDAC3 inhibition also triggers hyperacetylation of STAT3, suggesting crosstalk signaling between phosphorylation and acetylation of STAT3. Importantly, inhibition of HDAC3, but not HDAC1 or 2, significantly enhances bortezomib-induced cytotoxicity. Finally, we confirm that BG45 alone and in combination with bortezomib trigger significant tumor growth inhibition in vivo in a murine xenograft model of human MM. Our results indicate that HDAC3 represents a promising therapeutic target, and validate a prototype novel HDAC3 inhibitor BG45 in MM.
INTRODUCTION
A major challenge for molecular targeted therapy in multiple myeloma (MM) is its genetic complexity and molecular heterogeneity. Gene transcription within the tumor cell and its microenvironment can also be altered by epigenetic modulation (i.e., acetylation and methylation) in histones, and inhibition of histone deacetylases (HDACs) has therefore emerged as a novel targeted treatment strategy in MM and other cancers. 1 HDACs are divided into four classes: class-I (HDAC1, 2, 3 and 8), class-IIa (HDAC4, 5, 7 and 9), class-IIb (HDAC6 and 10), class-III (SIRT1-7) and class-IV (HDAC11). These classes differ in their subcellular localization (class-I HDACs are nuclear and class-II enzymes cytoplasmic), and their intracellular targets. Moreover, recent studies have identified non-histone targets of HDACs in cancer cells associated with various functions including gene expression, DNA replication and repair, cell cycle progression, cytoskeletal reorganization and protein chaperone activity.
Several HDAC inhibitors (HDACi) are currently in clinical development in MM, 2 and both vorinostat (SAHA) and romidepsin (FK228 or FR901228) have already received approval by the Food and Drug Administration for the treatment of cutaneous T-cell lymphoma. 3 Vorinostat is a hydroxamic acidbased HDACi that, like other inhibitors of this class including panobinostat (LBH589) and belinostat (PXD101), are generally non-selective with activity against class-I, -II and -IV HDACs. 4 The natural product romidepsin is a cyclic tetrapeptide with HDAC inhibitory activity primarily towards class-I HDACs. Other HDACi based on aminobenzamide biasing elements, such as mocetinostat (MGCD103) and entinostat (MS275), are highly specific for HDAC1, 2 and 3. Importantly, clinical trials with nonselective HDACi such as vorinostat combined with bortezomib have shown efficacy in MM, but have attendant fatigue, diarrhea and thrombocytopenia. 5 Our preclinical studies characterizing the biologic impact of isoform-selective HDAC6 inhibition in MM, using HDAC6 knockdown and HDAC6-selective inhibitor tubacin, 6 showed that combined HDAC6 and proteasome inhibition triggered dual blockade of aggresomal and proteasomal degradation of protein, massive accumulation of ubiquitinated protein and synergistic MM cell death. On the basis of these studies, a potent and selective HDAC6 inhibitor ACY-1215 (ref. 7) was developed, which is now demonstrating promise and tolerability in phase I/II clinical trials in MM. 8 In this study, we similarly determine whether isoform inhibition of class-I HDAC mediates cytotoxicity, without attendant toxicity to normal cells. We define the role of HDAC3-selective inhibition in MM cell growth and survival using both lentiviral HDAC3 knockdown and a novel small-molecule HDAC3-selective inhibitor BG45. Within class-I HDACs, our results show that HDAC3 represents a promising therapeutic target in MM, and that combined HDAC3 and proteasome inhibition mediates synergistic cytotoxicity. Our studies provide the preclinical rationale for derived clinical trials using HDAC3-selective inhibitors to both enhance MM cytotoxicity and improve tolerability.
MATERIALS AND METHODS Reagents
Non-selective HDACi LBH589 (panobinostat) and MS275 (entinostat), as well as HDAC6-selective inhibitor tubastatin-A were purchased from Selleck Chemicals (Houston, TX, USA). Bortezomib was also obtained from Selleck Chemicals. BG45 (N-(2-aminophenyl)pyrazine-2-carboxamide) and Merck60 (4- . MM cell lines were maintained in RPMI 1640 medium (Sigma-Aldrich, St Louis, MO, USA) supplemented with 10% fetal bovine serum, 2 mM L-glutamine (Invitrogen, Carlsbad, CA, USA), 100 U/ml penicillin and 100 U/ml streptomycin (Invitrogen). The 293T cells were maintained in Dulbecco's modified Eagle's medium (Sigma-Aldrich) supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 mg/ml streptomycin (Invitrogen).
Bone marrow (BM) specimens were obtained from patients with MM, and mononuclear cells were separated by Ficoll-Hipaque density sedimentation. Primary CD138 þ plasma cells from MM patients were obtained using negative selection, as in previous studies.
9 CD138 À BM mononuclear cells were used to establish long-term bone marrow stromal cell (BMSC) cultures, as described previously. 9 Peripheral blood mononuclear cells were collected from healthy volunteers to obtain mononuclear cells. All procedures were performed with IRB-approved (Dana-Farber Cancer Institute, Boston, MA, USA) protocols and informed consent, and in accordance with the Declaration of Helsinki protocol.
Cell growth inhibition assay
The growth inhibitory effects of Merck60, MS275, BG45, bortezomib and HDAC3 knockdown in MM cell lines were assessed by measuring 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide (MTT; Sigma-Aldrich) dye absorbance, as described previously. 10 To measure proliferation of MM cells, the rate of DNA synthesis was measured by [ 3 H]thymidine (Perkin-Elmer, Boston, MA, USA) uptake, as reported previously. 10 Immunoblotting and immunoprecipitation MM cells were harvested and lysed using sodium dodecyl sulfatepolyacrylamide gel electrophoresis sample buffer containing 60 mM Tris-HCl, pH 6.8, 2% sodium dodecyl sulfate, 10% glycerol, 0.005% bromophenol blue, 5 mM ethylenediaminetetraacetic acid, 5 mM NaF, 2 mM Na 3 VO 4 , 1 mM phenylmethylsulfonyl fluoride, 5 mg/ml leupeptin and 5 mg/ml aprotinin, and then heated at 100 1C for 5 min. After the determination of protein concentration using DC protein assay (Bio-Rad, Hercules, CA, USA), b-mercaptoethanol was added to the whole-cell lysates to a 2% final b-mercaptoethanol concentration. The whole-cell lysates were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to nitrocellulose membranes (Bio-Rad, Hercules, CA, USA) or polyvinylidene fluoride membranes (Millipore, Billerica, MA, USA) and immunoblotted with anti-histone H3, -HDAC1, -HDAC2, -HDAC3, -acetylhistone H2A (lysine 5), -acetyl-histone H2B (lysine 5), -acetyl-histone H3 (lysine 9), -acetyl-histone H4 (lysine 8), -glyceraldehyde-3-phosphate dehydrogenase (GAPDH), -poly (ADP-ribose) polymerase (PARP), -caspase-3, -caspase-8, -caspase-9, -signal transducers and activators of transcription 3 (STAT3), -phospho-STAT3 (p-STAT3) (tyrosine 705), -p-STAT3 (serine 727), -p21, -Janus kinase 2 (JAK2), -acetylated-lysine and antiphosphorylated-tyrosine antibodies (Abs; Cell Signaling Technology, Beverly, MA, USA).
For immunoprecipitation, MM cells were lysed with Nonidet P-40 buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Nonidet P-40, 5 mM ethylenediaminetetraacetic acid, 5 mM NaF, 2 mM Na 3 VO 4 , 1mM phenylmethylsulfonyl fluoride, 5 mg/ml leupeptin and 5 mg/ml aprotinin). Whole-cell lysates were incubated with anti-STAT3, -JAK2 and -green fluorescent protein Abs for 2 h at 4 1C, and then incubated with Protein A/G PLUS-Agarose (Santa Cruz Biotechnology, Dallas, TX, USA) overnight at 4 1C. Anti-green fluorescent protein Ab served as a control. Immune complexes were analyzed by immunoblotting with anti-STAT3, -JAK2, -acetylated-lysine and -phosphorylated-tyrosine Abs.
Transfection of short hairpin RNA HDAC1, HDAC2 and HDAC3 pLKO.1 short hairpin RNA (shRNA) vectors were obtained from the RNA Interference Screening Facility at the Dana-Farber Cancer Institute. Recombinant lentivirus was produced and infection of MM cells was performed as described previously. Synthesis of tert-butyl (2-aminophenyl)carbamate (2) To a stirring solution of benzene-1,2-diamine (1.0 g, 9.247 mmol) and 4-dimethylminopyridine (50 mg) in tetrahydrofuran (20 ml), a solution of di-tert-butyl dicarbonate (1.009 g, 4.6236 mmol) in dichloromethane (20 ml) was added dropwise at room temperature. The reaction mixture was evaporated in a rotary evaporator and purified by column chromatography using hexane and ethylacetate solvent mixture (80:20) to obtain the desired mono-Boc protected compound 2 (0.380 g, 20% yield).
Synthesis of tert-butyl (2-(pyrazine-2-carboxamido)phenyl)carbamate (3)
Compound 3 was synthesized following aromatic acid and aromatic amine coupling reactions, where pyrazine-2-carboxylic acid (0.03 g, 0.242 mmol) was dissolved in dichloromethane/pyridine (1:1) mixture, and 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide (0.051 g, 0.266 mmol) was added and stirred for 10 min. Tert-butyl (2-aminophenyl)carbamate (0.061 g, 0.29 mmol) and catalytic amounts of 4-dimethylminopyridine were added at room temperature, and stirring was continued to 2 h. The reaction mixture was evaporated, and crude mixture was resuspended into ethyl acetate and extracted from aqueous NaHCO 3 solution. After evaporating the EtOAc layer, the titled compounds were purified by column chromatography using ethyl acetate methanol (9:1) solvent system to obtain the desired compound 3 (0.024 g, 31.6% yield).
Synthesis of N-(2-aminophenyl)pyrazine-2-carboxamide (4)
The final compound is made by deprotection of Boc group from tert-butyl (2-(pyrazine-2-carboxamido)phenyl)carbamate using dichloromethane and trifluoroacetic acid (1:1) mixture at room temperature for 30 min, which was then made free base by suspending the crude mixture into NaHCO 3 (aq) solution and extraction into dichloromethane. The organic layer was evaporated to obtain the pure final compound with quantitative yield (0.016 g). Inhibitory activity of BG45 against individual HDAC isoforms was determined as described previously. 12 Murine xenograft models CB17 severe combined immunodeficiency mice (48-54 days old) were purchased from Charles River Laboratories (Wilmington, MA, USA). All animal studies were conducted according to protocols approved by the Animal Ethics Committee of the Dana-Farber Cancer Institute. After irradiation (200 cGy), mice were subcutaneously injected with 5 Â 10 two times a week. Tumor size was measured every 3 days, and tumor volume was calculated with the formula:
2 ), where 'a' is the long diameter of the tumor and 'b' is the short diameter of the tumor. Mice were killed when the tumor reached 2 cm in length or 2 cm 3 volume, or if mice appeared moribund to prevent unnecessary morbidity. Survival was evaluated from the first day of the treatment until death.
Statistical analysis
The combined effect of drugs was analyzed by isobologram analysis using the Compusyn software program (ComboSyn Inc, Paramus, NJ, USA); a combination indexo1 is indicative of a synergistic effect. In the murine xenograft studies, statistical significance was determined by Student's t-test. The minimal level of significance was Po0.05.
RESULTS

MS275 is more cytotoxic than Merck60 in MM cells
Non-selective HDACi have demonstrated variable anti-MM activity in preclinical studies. We first examined the growth inhibitory effect of Merck60 (HDAC1 and 2 inhibitor) versus MS275 (HDAC1, 2 and 3 inhibitor) in MM cell lines using MTT assay. MS275 triggered significant MM cell growth inhibition, whereas Merck60 induced only a modest growth inhibition effect (Figure 1a) . Immunoblotting confirmed that all MM cell lines express HDAC1, 2 and 3 proteins (Figure 1b) . We next examined the effects of these agents on acetylation of histones in RPMI8226 MM cells. Importantly, MS275 in a dose-dependent manner more potently induced acetylation of histones (H2A, H2B, H3 and H4) and increased p21 WAF1 expression than Merck60 (Figure 1c ). These results suggest that HDAC3 has an important role in MM cell growth and/or survival.
HDAC3 knockdown inhibits MM cell growth To determine that the MM cell growth inhibitory effect of MS275 is predominantly due to HDAC3 inhibition, we next performed knockdown of HDAC isoforms (HDAC1, 2 and 3) using a lentiviral shRNA infection system. We first confirmed isoform-selective HDAC1, 2 or 3 knockdown in RPMI8226 MM cells by immunoblotting (Figure 2a) . Importantly, HDAC3 knockdown triggered the most significant growth inhibitory effect in RPMI8226 cells, assessed by both [ 3 H]thymidine uptake ( Figure 2b ) and MTT assay (Figure 2c ). In contrast, HDAC1 knockdown induced only modest growth inhibition, and no growth inhibitory effect was observed after HDAC2 knockdown, further confirming that HDAC3 has a crucial role in MM cell growth and survival. The molecular mechanism whereby HDAC3 knockdown triggers MM cell growth inhibition was further examined. HDAC3, but not HDAC1 or 2, knockdown induces caspase-3 and PARP cleavage (Figure 2d ). We also examined the effects of HDAC1, 2 or 3 knockdown on acetylation of histones in RPMI8226 cells. As shown in Figure 2e , there is no significant difference in the pattern of histone lysine acetylation between isoform-selective HDAC1, 2 or 3 knockdown cells. Taken together, these results suggest that HDAC3 Previous studies have shown that HDAC3 alters STAT3 phosphorylation in other cell types, 13, 14 and we have previously shown that JAK2/STAT3 pathway has an important role in MM cell survival. [15] [16] [17] [18] We therefore next first examined whether nonselective HDACi LBH589 modulated p-STAT3 in MM cells. We observed that p-STAT3 was significantly inhibited by LBH589 treatment in MM.1S, U266 and INA-6 cells ( Figure 3a) . As p-STAT3 can be upregulated in the context of the BM microenvironment, we examined whether inhibition of p-STAT3 by LBH589 treatment of MM.1S cells was maintained even in the presence of exogenous IL-6 or BMSC culture supernatants. Both IL-6 and BMSC culture supernatants markedly upregulated p-STAT3, which was blocked by LBH589 (Figure 3b ). Other non-selective HDACi (TSA, SAHA) also downregulated p-STAT3 (Figure 3c ). To determine whether downregulation of p-STAT3 induced by non-selective HDACi is mediated via HDAC3 inhibition, we next examined p-STAT3 in HDAC3 knockdown MM cells. Both tyrosine (Y705) and serine (S727) phosphorylation of STAT3 were markedly downregulated in HDAC3 knockdown cells, without inhibition of p-ERK (Figure 3d) . Importantly, no downregulation of p(Y705)-STAT3 was observed in HDAC1 or HDAC2 knockdown cells (Figure 3e ), further confirming As STAT3 can be acetylated at lysine 685, 19 we next examined whether HDAC3 knockdown affects STAT3 acetylation. As shown in Figure 3f (left panel), STAT3 was hyperacetylated in HDAC3 knockdown RPMI8226 cells; however, the cross-talk between STAT3 phosphorylation and acetylation remains unclear. Interestingly, phosphorylation of JAK2, an upstream molecule of STAT3, was upregulated in HDAC3 knockdown cells (Figure 3f , right panel), suggesting a possible positive feedback loop associated with downregulated p-STAT3. These results suggest that HDAC3 knockdown directly inhibits phosphorylation on both Y705 and S727 of STAT3.
HDAC3-selective inhibitor triggers significant MM cell growth inhibition To both further validate the role of HDAC3 in MM biology and provide the framework for derived clinical trials targeting HDAC3, we have recently produced and validated the orthoamino anilide BG45 to be an HDAC class-I inhibitor with selectivity for HDAC3 (half-maximal inhibitory concentration ¼ 289nM) over HDAC1 and 2 (Supplementary Figure 2b and Table 1) . 12 Consistent with HDAC3 knockdown data above, BG45 significantly inhibited MM cell growth in a dose-dependent manner, as assessed by MTT assay (Figure 4a) . Importantly, BG45 also triggered a potent growth inhibitory effect against patient-derived MM cells (Figure 4b ), without affecting normal donor peripheral blood mononuclear cells (Figure 4c ). These results suggest that BG45 selectively targets shRNAs. Whole-cell lysates were subjected to IB with anti-STAT3, -p-STAT3 (Tyr705), -p-STAT3 (Ser727), -p-ERK1/2, -ERK1/2 and -GAPDH Abs. (e) RPMI8226 cells were infected with Luc or HDAC1 (nos. 1 and 2), HDAC2 (nos. 1 and 2) or HDAC3 (nos. 1 and 2) shRNAs. Whole-cell lysates were subjected to IB with anti-p-STAT3 (Tyr705), -STAT3 and -GAPDH Abs (f ) and (g) RPMI8226 cells were infected with either Luc or HDAC3 (nos. 1 and 2) shRNAs. Whole-cell lysates were immunoprecipitated (IP) with (f ) anti-green fluorescent protein or -STAT3 or (g) -JAK2 Abs.
Immunoprecipitates were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotted with (f) Ac-lysine and STAT3 or (g) p-tyrosine and JAK2.Abs. HDAC3 is a novel target in myeloma J Minami et al We further assessed the mechanism of the HDAC inhibitory effect by BG45 by profiling its effect on histone acetylation in MM cells. BG45 in a dose-dependent manner significantly induced acetylation of histone H2A, H3 and H4 in MM.1S cells (Figure 4f,  left panel) . In contrast, BG45 treatment did not increase a-tubulin acetylation, a biomarker of HDAC6 inhibition (Figure 4f , right panel), further indicating its selectivity against HDAC3. In contrast, the non-selective HDACi LBH589 significantly triggered both histone and a-tubulin acetylation. We next examined the impact of BG45 on STAT3 phosphorylation in MM.1S cells. Consistent with the results obtained for HDAC3 knockdown, BG45 in a dosedependent manner markedly downregulated p-STAT3, without affecting p-ERK1/2 (Figure 4g ). Importantly, we also observed that BG45 increased acetylation of STAT3 in MM.1S cells (Figure 4h ). Taken together, these results demonstrate that the HDAC3-selective inhibitor BG45-induced MM cell toxicity is associated with hyperacetylation of histones and STAT3, as well as downregulation of p-STAT3.
HDAC3 inhibition synergistically enhances bortezomib-induced cytotoxicity. Non-selective HDACi show only modest anti-MM activities as single agents, which can be markedly enhanced in combination with bortezomib. 6, 7 We have also shown that HDAC6-selective inhibitors tubacin and ACY1215 synergistically augment bortezomib-induced cytotoxicity towing to dual blockade of proteasomal and aggresomal protein degradation, evidenced by accumulation of ubiquitinated proteins. 6, 7 However, the mechanism underlying the synergistic effect of bortezomib combined with class-I HDACi has not yet been defined. We therefore next examined combination treatment of RPMI8226 cells with bortezomib and either Merck60 or MS275. Importantly, we observed synergistic cytotoxicity triggered by bortezomib in combination with MS275, but not with Merck60 ( Figure 5a and Table 2 ). Moreover, bortezomib significantly enhances cytotoxicity in HDAC3 knockdown cells (Figure 5b ), indicating that HDAC3 has a key role in mediating the synergistic anti-MM activity induced by class-I HDACi with bortezomib. We have previously shown that bortezomib upregulates Akt activity, which can be inhibited by Akt inhibitor perifosine, and that combined therapy with bortezomib and perifosine tiggers synergistic cytotoxicity in MM cells. 9 As previous studies have shown that bortezomib upregulates activated STAT3 in head and neck squamous cell carcinoma, 21 we here similarly examined whether bortezomib enhances p-STAT3 in MM cells. Importantly, we observed that bortezomib upregulated p-STAT3, which is completely abrogated in HDAC3, but not in HDAC1 or HDAC2, knockdown cells (Figure 5c ). These results suggest that the synergistic cytotoxicity induced by combined HDAC3 knockdown with bortezomib is mediated, at least in part, by inhibition of STAT3 activity.
We similarly evaluated the combination effect of bortezomib with selective HDAC3 inhibitor BG45. Of note, BG45 did not inhibit HDAC6 evidenced by hyperacetylation of a-tubulin (Supplementary Figure 3a) . Consistent with HDAC3 knockdown data, BG45 in a dose-dependent manner also synergistically enhanced bortezomib-induced cytotoxicity (Figure 5d and Table 2C ). We also examined whether dual inhibition of both HDAC3 and HDAC6 was more cytotoxic than either HDAC3 or HDAC6 when combined with bortezomib. As expected, HDAC6-selective inhibitor tubastatin-A further enhanced cytotoxicity induced by combined HDAC3 knockdown with bortezomib ( Supplementary Figure 3b) . BG45 demonstrate significant anti-MM activities in a murine xenograft model To evaluate the in vivo impact of BG45 alone or in combination with bortezomib, we used the subcutaneous MM.1S xenograft model of human MM in mice. BG45 significantly inhibited MM tumor growth in the treatment versus control group in a dosedependent manner. For example, significant differences were observed in control versus BG45 15 mg/kg, control versus BG45 50 mg/kg and BG45 15 mg/kg versus BG45 50 mg/kg at day 22 (Po0.05; Figure 6a ). Moreover, BG45 50 mg/kg in combination with bortezomib further enhanced either single agent activity (Po0.01). Representative images of tumor growth inhibition by BG45 (50 mg/kg) are demonstrated in Figure 6b . These results confirmed that BG45 triggers in vivo anti-MM activities.
DISCUSSION
HDACs regulate the activity of tumor suppressor genes and oncogenes that have pivotal roles in tumorigenesis 22 and have been investigated in preclinical studies in both solid tumors and hematologic malignancies, including MM. 4, 23 However, the clinical utility of these agents is limited because unfavorable toxicities attendant to non-selective HDAC inhibition. Indeed, non-selective HDACi show different inhibitory profiles of class-I to class-IV DACs. 12 To date, however, the biologic impact of isoform-selective HDACi on MM cell growth and/or survival has not yet been elucidated. Interestingly, previous studies have shown that selective inhibition of HDAC1 and 2 by Merck60 treatment triggers significant growth inhibition in B-cell acute lymphocytic leukemia cells. 24 We here observed that MS275 (HDAC1, 2 and 3 inhibition) induces significantly greater MM cell growth inhibition than Merck60 (HDAC1 and 2 inhibition), and demonstrate the biologic impact of HDAC3 inhibition on MM cell growth and survival in the context of the BM microenvironment using combined genetic and pharmacological probes.
We examined the biologic impact of HDAC3 in MM cells using HDAC3 knockdown and HDAC3-selective small-molecule inhibitor BG45. Both induce significant growth inhibition in MM cell lines and patient MM cells, without toxicity in peripheral blood mononuclear cells. In contrast, modest or no growth inhibitory effect of HDAC1 or HDAC2 knockdown was recognized. Consistent with our previous studies using non-selective HDACi (i.e., SAHA, LAQ824, LBH589), [25] [26] [27] the MM cell growth inhibitory effect induced by either HDAC3 knockdown or BG45 is associated with markedly increased p21 WAF1 , followed by apoptosis evidenced by cleavage of caspases and PARP. Taken together, these results strongly suggest that class-I HDACi-or non-selective HDACiinduced MM cell growth inhibition is due to HDAC3 inhibition. They further suggest that more selective HDAC3 inhibitor may HDAC3 is a novel target in myeloma J Minami et al have a more favorable side-effect profile than class-I or nonselective HDACi. We have previously shown that both non-selective HDACi and HDAC6-selective inhibitors tubacin and ACY-1215 significantly enhance bortezomib-induced cytotoxicity in MM cells, associated with dual proteasome and aggresome blockade. 6, 7 As nonselective HDACi can block both class-I (HDAC1, 2, 3 and 8) and class-IIb (HDAC6 and 10), we next determined whether the enhanced cytotoxicity of bortezomib combined with non-selective HDACi is due solely to HDAC6 inhibition, or also to class-I HDAC blockade. Importantly, MS275, but not Merck60, augments bortezomib-induced cytotoxicity in MM cells. Moreover, both HDAC3 knockdown and BG45 similarly significantly enhance bortezomib-induced cytotoxicity, confirming the pivotal role of HDAC3 blockade in mediating enhanced cytotoxicity in combination with bortezomib. Bortezomib with HDAC6 inhibitors achieves dual inhibition of proteasomal and aggresomal protein degradation and accumulation of polyubiquitinated proteins, 6, 7 which was not observed by bortezomib and HDAC3 knockdown. Therefore, differential mechanisms of action of HDAC3 (class-I) versus HDAC6 (class-IIb) inhibition mediate enhanced bortezomibinduced cytotoxicity in MM cells.
We have shown that the BM microenvironment induces MM cell proliferation, survival, drug resistance and migration. 20, 28 The JAK2/STAT3 pathway mediates MM cell survival by regulating antiapoptotic proteins including Mcl-1, Bcl-xL and survivin; 17, [29] [30] [31] therefore, inhibition of JAK2/STAT3 pathway is a potential therapeutic target. Indeed, we and others have shown that STAT3 inhibition by RNAi or small-molecule inhibitors significantly inhibits MM cell growth. 15, 17, 32 Importantly, we here found that HDAC3 knockdown markedly decreases both tyrosine (Y705) and serine (S727) phosphorylation of STAT3. Moreover, either HDAC3 knockdown or BG45 inhibit p-STAT3 and MM cell growth, even in the presence of exogenous IL-6 or BMSC culture supernatants.
Previous studies have shown that STAT3 acetylation is regulated by HDAC3 in multiple cancers, 14, 19, 33 indicating that STAT3 is one of non-histone substrate proteins were hyperacetylated by HDAC3 inhibition. We therefore examined the impact of HDAC3 inhibition on STAT3 acetylation. Consistent with previous studies, we observed that acetylation of STAT3 in MM cells is upregulated by both HDAC3 knockdown and BG45. As HDAC3 knockdown or inhibition triggers both upregulation of acetylation and downregulation of phosphorylation of STAT3, these results suggest crosstalk signaling, and that hyperacetylation may inhibit phosphorylation of STAT3. Previous studies have also shown that HDAC3 knockdown upregulates acetylation of STAT3 and downregulates p-STAT3 in diffuse large B-cell lymphoma cells; 14 however, the precise mechanism is unknown and is the object of our ongoing studies. Importantly, HDAC6 inhibition enhances cytotoxicity induced by HDAC3 knockdown with bortezomib, further suggesting differential mechanisms of action whereby HDAC6 inhibition versus HDAC3 inhibition enhances bortezomib-induced cytotoxicity.
In summary, we demonstrated remarkable growth inhibitory effect of BG45, alone and in combination, in a murine xenograft model of human MM cells. Our results therefore demonstrate the role of HDAC3 in MM cell growth in the BM microenvironment and provide the preclinical rationale for targeting HDAC3, alone and in combination with proteasome inhibitors, to improve patient outcome in MM.
